AngioDynamics Launches PATHFINDER I Registry to Evaluate Performance and Clinical Outcomes of the AURYON™ Atherectomy System
The AURYON Atherectomy System, previously known as the Eximo B-Laser, is a proprietary 355nm wavelength laser-technology platform that was acquired by
“The PATHFINDER I study will provide valuable, scientifically backed data to further differentiate the AURYON system from competitive products in this space and build upon the excellent long-term results that patients experienced during the IDE,” said
AngioDynamics’ PATHFINDER I Registry is a prospective, non-randomized, single arm, multicenter observational study that will evaluate the performance of the AURYON Atherectomy System during procedures and measure clinical outcomes, both intermediate and long-term. A total of 100 eligible PAD patients treated with the AURYON Atherectomy System in a post-market setting will be enrolled and tracked for a 36-month period after the initial procedure.
Initial findings from the pilot registry study will contribute to a subsequent large pivotal phase registry that is expected to include approximately 1,000 patients. Visit www.clinicaltrials.gov/ct2/show/NCT04229563 for more information about the PATHFINDER I Registry.
As previously communicated, the commercial release of the AURYON Atherectomy System in
Investor Relations Contact: